Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Florida: - Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063) — Boca Raton, Florida
- Clermont Oncology Center ( Site 0046) — Clermont, Florida
- Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
- Florida Cancer Specialists - East ( Site 7002) — West Palm Beach, Florida
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- University of Florida Health Shands Children's Hospital — Gainesville, Florida
- Nemours Children's Specialty Care Jacksonville — Jacksonville, Florida
- Nemours Children's Hospital - Orlando — Orlando, Florida
- Saint Joseph's Hospital - Tampa — Tampa, Florida
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Florida: - University of Miami — Miami, Florida
- Moffitt Cancer Center & Research Institute — Tampa, Florida
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Florida: - Malcolm Randall V.A. Medical Center /ID# 267825 — Gainesville, Florida
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713 — Jacksonville, Florida
- Mid Florida Hematology And Oncology Center /ID# 269159 — Orange City, Florida
- Comprehensive Hematology Oncology /ID# 267644 — St. Petersburg, Florida
Phase 2, Phase 3 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2/3 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloi…
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Florida: - University of Florida Health Shands Cancer Hospital — Gainesville, Florida
- Mayo Clinic Florida — Jacksonville, Florida
- Orlando Health Cancer Institute — Orlando, Florida
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Florida: - Florida Oncology and Hematology — Fort Myers, Florida
- Baptist Md Anderson Cancer Center — Jacksonville, Florida
- Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Florida: - Memorial Hospital West ( Site 5410) — Pembroke Pines, Florida
Phase 3 Recruiting Academic/Other
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and a…
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT ID: NCT07223814
Sites in Florida: - US-Orlando FL-ORLANDOHEALTH — Orlando, Florida
Phase 3 Recruiting Industry
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06104566
Sites in Florida: - Ascentage Investigative Site — Jacksonville, Florida
- Ascentage Investigative Site — Miami Beach, Florida
Phase 3 Recruiting Industry
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once ever…
Sponsor: Grifols Biologicals, LLC
NCT ID: NCT07582432
Sites in Florida: - Study Site 102 — St. Petersburg, Florida
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Florida: - Mayo Clinic in Florida — Jacksonville, Florida
- Miami Cancer Institute — Miami, Florida
- Memorial Hospital West — Pembroke Pines, Florida
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- AdventHealth Orlando — Orlando, Florida
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
Phase 2 Recruiting Industry
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Florida: - University of Miami — Coral Gables, Florida
- Florida Cancer Specialists — Sarasota, Florida
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Florida: - University of Florida — Gainesville, Florida
- Nicklaus Children's Hospital — Miami, Florida
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida
Phase 2 Recruiting NIH
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibit…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06311227
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
Phase 1, Phase 2 Recruiting Industry
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/r…
Sponsor: Sellas Life Sciences Group
NCT ID: NCT04588922
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chroni…
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT ID: NCT06163430
Sites in Florida: - Florida Cancer Specialists - South Region Research Office — Fort Myers, Florida
- Florida Cancer Affiliates - Ocala — Ocala, Florida
- Florida Cancer Specialists - North Region Research Office — St. Petersburg, Florida
- Florida Cancer Specialists - East Region Research Office — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Florida: - Johns Hopkins All Children's Hospital ( Site 1025) — St. Petersburg, Florida
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants w…
Sponsor: AstraZeneca
NCT ID: NCT06137118
Sites in Florida: - Research Site — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Florida: - Mayo Clinic, Clinical Trials Referral Office — Jacksonville, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acu…
Sponsor: Chordia Therapeutics, Inc.
NCT ID: NCT05732103
Sites in Florida: - Mayo Clinic Florida — Jacksonville, Florida